Vitae Pharmaceuticals Inc. (NASDAQ:VTAE)’s share price traded down 1.9% on Tuesday . The stock traded as low as $7.59 and last traded at $7.60, with a volume of 60,191 shares traded. The stock had previously closed at $7.75.

Several equities analysts recently weighed in on the company. Zacks Investment Research downgraded Vitae Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday, May 4th. JMP Securities downgraded Vitae Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Wedbush restated an “outperform” rating and issued a $23.00 price objective on shares of Vitae Pharmaceuticals in a report on Wednesday, May 25th. Finally, Wells Fargo & Co. restated a “buy” rating on shares of Vitae Pharmaceuticals in a report on Friday, June 10th. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $16.65.

The company has a 50-day moving average price of $9.64 and a 200-day moving average price of $8.51. The stock’s market cap is $205.92 million.

Vitae Pharmaceuticals (NASDAQ:VTAE) last issued its earnings results on Wednesday, August 3rd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.05. During the same period last year, the firm earned ($0.45) earnings per share. The company’s revenue was down 98.0% compared to the same quarter last year. Analysts anticipate that Vitae Pharmaceuticals Inc. will post ($1.64) earnings per share for the current year.

An institutional investor recently bought a new position in Vitae Pharmaceuticals stock. Dimensional Fund Advisors LP bought a new position in Vitae Pharmaceuticals Inc. (NASDAQ:VTAE) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 73,607 shares of the company’s stock, valued at approximately $1,332,000. Dimensional Fund Advisors LP owned 0.34% of Vitae Pharmaceuticals as of its most recent filing with the SEC.

Vitae Pharmaceuticals, Inc is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company’s product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.